e-learning
resources
Virtual 2021
07.09.2021
Advances in asthma treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy
J. Kroes (Leeuwarden, Netherlands), S. Zielhuis (Groningen, Netherlands), K. De Jong (Leeuwarden, Netherlands), S. Zielhuis (Leeuwarden, Netherlands), E. Van Roon (Groningen, Netherlands), E. Bel (Amsterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands)
Source:
Virtual Congress 2021 – Advances in asthma treatment
Session:
Advances in asthma treatment
Session type:
E-poster
Number:
3537
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Kroes (Leeuwarden, Netherlands), S. Zielhuis (Groningen, Netherlands), K. De Jong (Leeuwarden, Netherlands), S. Zielhuis (Leeuwarden, Netherlands), E. Van Roon (Groningen, Netherlands), E. Bel (Amsterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands). Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy. 3537
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma
Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science
Year: 2021
Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma
Source: International Congress 2019 – Powerful cohort studies with/without lung function
Year: 2019
Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018
Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase
Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations
Year: 2021
Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma.
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy.
Source: International Congress 2018 – New pharmacological strategies in airway diseases
Year: 2018
Stopping
versus
continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)
Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021
Year: 2022
Efficacy of short-term high dose predonisolone therapy in acute exacerbation of bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001
Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020
Late Breaking Abstract: Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
Predictors of successful oral steroid tapering in severe, prednisone-dependent asthma
Source: Annual Congress 2010 - Cough, airway hyperresponsiveness and asthma control
Year: 2010
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Source: International Congress 2017 – Asthma management
Year: 2017
Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018
Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD
Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept